These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

350 related items for PubMed ID: 15802276

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22. A systematic review of the role of bisphosphonates in metastatic disease.
    Ross JR, Saunders Y, Edmonds PM, Patel S, Wonderling D, Normand C, Broadley K.
    Health Technol Assess; 2004; 8(4):1-176. PubMed ID: 14960258
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Optimizing clinical benefits of bisphosphonates in cancer patients with bone metastases.
    Aapro M, Saad F, Costa L.
    Oncologist; 2010; 15(11):1147-58. PubMed ID: 21051658
    [Abstract] [Full Text] [Related]

  • 27. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial.
    Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein MA, Coleman RE, Reitsma DJ, Chen BL, Seaman JJ.
    Cancer; 2003 Oct 15; 98(8):1735-44. PubMed ID: 14534891
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Use of bisphosphonates in metastatic breast cancer: single institution review at the Dr. H. Bliss Murphy Cancer Centre.
    Murphy L, McCarthy J, McCrate F, Laing K, Powell E, Seal M, Edwards S.
    Support Care Cancer; 2013 Jun 15; 21(6):1557-60. PubMed ID: 23334521
    [Abstract] [Full Text] [Related]

  • 30. Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial.
    Cartenì G, Bordonaro R, Giotta F, Lorusso V, Scalone S, Vinaccia V, Rondena R, Amadori D.
    Oncologist; 2006 Jun 15; 11(7):841-8. PubMed ID: 16880243
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. The role of bisphosphonates in breast cancer.
    Coleman RE.
    Breast; 2004 Dec 15; 13 Suppl 1():S19-28. PubMed ID: 15585379
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan.
    Henk HJ, Kaura S.
    J Med Econ; 2012 Dec 15; 15(1):175-84. PubMed ID: 22017235
    [Abstract] [Full Text] [Related]

  • 38. Efficacy of clodronate, pamidronate, and zoledronate in reducing morbidity and mortality in cancer patients with bone metastasis: a meta-analysis of randomized clinical trials.
    Machado M, Cruz LS, Tannus G, Fonseca M.
    Clin Ther; 2009 May 15; 31(5):962-79. PubMed ID: 19539097
    [Abstract] [Full Text] [Related]

  • 39. Cost-effectiveness of oral ibandronate compared with intravenous (i.v.) zoledronic acid or i.v. generic pamidronate in breast cancer patients with metastatic bone disease undergoing i.v. chemotherapy.
    De Cock E, Hutton J, Canney P, Body JJ, Barrett-Lee P, Neary MP, Lewis G.
    Support Care Cancer; 2005 Dec 15; 13(12):975-86. PubMed ID: 15871033
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.